CL7 Commits $420,000 in New Research Grants to Strike Out Ewing’s Sarcoma
We are absolutely thrilled to announce that The Charlie Landers Foundation (CL7) has committed $420,000 in funding as part of our third round of research grants. Let’s go!!!!
We tip a cap to the following investigative researchers and their labs for the important work they are doing to strike out Ewing’s Sarcoma for warriors just like Charlie.
We are indebted to our far-reaching and beloved CL7 community for their unflagging support. And to our CL7 Medical Advisory Board — thank you for your expertise, commitment, and guidance in making these determinations.
Dr. John H. Bushweller – University of Virginia
“Small molecule inhibitors of EWS::FLI1(ERG) DNA binding, a novel approach to Ewing’s Sarcoma therapy“
$150,000
Dr. Marc Ladanyi – Memorial Sloan Kettering Cancer Center (MSKCC), Ladanyi Laboratory
“Diverse secondary genetic alterations converge functionally to induce a more repressive profile of regulatory marks on Histone H3 in a clinically aggressive subset of Ewing Sarcoma: Opportunities for discovery and drug testing“
$119,895
Jason Price, PhD – Seattle Children’s Research Institute
“Targeting the Ewing Sarcoma extracellular matrix to eliminate minimal residual disease and prevent metastatic progression“
$150,000
To date, more than $1.1 million in grants and direct donations has been allocated by CL7 to top investigative researchers around the country. And as we like to say — we’re just getting started. We are hellbent on moving the needle and seeing real advancements in therapies and outcomes.
Let’s goooooooooo!!!! 💙🎗️
